101 filings
Page 2 of 6
8-K
lm8 pis29d
17 Nov 22
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
7:30am
8-K
m99sbcmq
2 Nov 22
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
6:49am
8-K
hhk0mlj rte5
3 Aug 22
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
6:46am
8-K
6yb2i
13 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
kyelckk
4 May 22
Editas Medicine Announces First Quarter 2022 Results and Business Updates
7:00am
8-K
3ch kj3el9xo8c23aveg
14 Apr 22
Departure of Directors or Certain Officers
7:40am
8-K
zx03yd3x4evj
24 Feb 22
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
6:47am
8-K
ewx 4v8kmsb5ag
7 Feb 22
Departure of Directors or Certain Officers
4:20pm
8-K
zwqs3 un8t1c4eznol
8 Nov 21
Editas Medicine Announces Third Quarter 2021 Results and Business Updates
7:16am
8-K
dks7nfz 3x2
28 Oct 21
Departure of Directors or Certain Officers
9:10am
8-K
4kiaua vk
29 Sep 21
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
9:05am
8-K
nmqk w1lu8
8 Sep 21
Departure of Directors or Certain Officers
4:21pm
8-K
85b6fhexs 3hyn5
4 Aug 21
Editas Medicine Announces Second Quarter 2021 Results and Business Updates
7:16am
8-K
zuqwm3 0m
8 Jun 21
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
361t8p3cojiztkusd
14 May 21
Entry into a Material Definitive Agreement
4:57pm
8-K
mjlattzf6
5 May 21
Editas Medicine Announces First Quarter 2021 Results and Update
7:10am
8-K
glvcj1cep ugoh9i
25 Feb 21
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
7:53am
8-K/A
vbpgdnwewcz
19 Feb 21
Departure of Directors or Certain Officers
4:15pm
8-K
nwjo9
8 Feb 21
Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer
8:10am
8-K
27ty9dvue 91ne
21 Jan 21
Editas Medicine Announces Pricing of Offering of Common Stock
4:47pm